Medically Reviewed
As experience with immunotherapy drugs grows, experts are getting a better sense of how best and when to use them.
Shutterstock
For years, the standard treatment for early stage non-small-cell lung cancer that hasn’t spread beyond the lungs has been chemotherapy given either before or after surgery to kill off any microscopic remaining tumor that may have spread before the surgery.
The results, however, were less than ideal.
“Even when surgery goes well, the cancer returns in more than half the patients, and many then die from their disease,” says Nicolas Girard, MD, head of medical oncology at the Curie Institute in Paris, France.
Operator
Good morning, and thank you for joining the GlycoMimetics call. At this time, all participants are in listen-only mode. Following management s remarks, we will hold a question-and-answer session. And at that time, the lines will be opened for you. [Operator Instructions]
I would now like to turn the call over to Shari Annes of Investor Relations Group at GlycoMimetics. Please go ahead.
Shari Annes
Investor Relations
Good morning. Today, we will review our accomplishments and financial results for the period ended March 31, 2021. We ll also update you on recent achievements. The press release we issued this morning is available on the company s website at www.glycomimetics.com under the Investors tab. This call is being recorded. A dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available on the Investor Relations section of the company s website for 30 days.
GlycoMimetics Inc (GLYC) Q1 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Topical therapy can help safely reduce side effect of cancer treatment
Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma, according to a study led by researchers at the UCLA Jonsson Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center.
For the past decade, epidermal growth factor receptor (EGFR) inhibitors have helped prolong the lives of patients with many advanced cancers, including cancers in the lung, head and neck, colorectal, breast, bladder and pancreas. While these targeted therapy drugs are highly effective at keeping the cancer at bay, they can cause patients to develop acneiform lesions, a type of skin rash that looks like acne bumps and frequently leads to impaired quality of life and drug discontinuation.